Search clinical trials for: ASG-22ME

Total 9 results

Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)

Urothelial Cancer

United States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand and more
Merck Sharp & Dohme LLC
Seagen Inc.; Astellas Pharma Global Development, Inc.

Recruiting

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Urinary Bladder Cancer, Muscle-invasive

United States, Australia, Belgium, Canada, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, Philippines, Poland, Russian Federation, Singapore, South Africa, Spain, Sweden, Thailand, T... and more
Astellas Pharma Global Development, Inc.
Seagen Inc.

Active, not recruiting

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Bladder Cancer | Urothelial Cancer | Ureteral Cancer

United States, Japan, Korea, Republic of, Taiwan, Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, Switzerland, United Kingdom
Astellas Pharma Inc
Seagen Inc.; Agensys, Inc.

Completed

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Neoplasms | Tumors | Medical Oncology

United States, Canada
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

Metastatic Urothelial Carcinoma | Urothelial Neoplasms

Australia, United States, Canada, Chile, France, Israel, Italy, Korea, Republic of, Netherlands, Spain, Taiwan, United Kingdom
Astellas Pharma Global Development, Inc.
Seagen Inc.

Completed

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

United States, Canada
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Active, not recruiting

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Italy, Spain, Canada, France, Puerto Rico
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Korea, Republic of, Spain, France, Germany, Italy, Japan, Netherlands
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Cancer

Japan

Search clinical trials for: ASG-22ME

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations